FIELD: pharmaceutics.
SUBSTANCE: invention refers to an agent for reducing pathological changes in prostatic hyperplasia, including dihydroquercetin, characterized by that it additionally contains oxidised dextran, dimexide, EDTA, polyethylene oxide in the following proportions: oxidised dextran - 1.25 wt %; dimexide - 5.0 wt %; EDTA - 2.5 wt %; dihydroquercetin - 2.5 wt %; polyethylene oxide 6000 - 88.75 wt %.
EFFECT: obtained agent improves efficiency of reducing pathological manifestations of prostatic hyperplasia.
1 cl, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING CHRONIC CALCULOUS PROSTATITIS | 2013 |
|
RU2534853C1 |
| MEANS FOR TREATMENT OF CHRONIC PROSTATITIS | 2007 |
|
RU2342940C1 |
| PREPARATION FOR TREATMENT OF PROSTATIC GLAND DISEASES MADE IN FORM OF A SUPPOSITORY | 2019 |
|
RU2752588C2 |
| AGENT FOR TREATMENT AND PREVENTION OF BENIGN HYPERPLASIA OF PROSTATE, PROSTATITIS, IMPOTENCY, STERILITY AND PROSTATE CANCER AND METHOD OF ITS APPLICATION | 2007 |
|
RU2336894C1 |
| PREPARATION FOR TREATING CHRONIC PROSTATITIS | 2006 |
|
RU2306145C1 |
| RECTAL SUPPOSITORY WITH PROPOLIS | 2002 |
|
RU2207138C1 |
| RECTAL SUPPOSITORIES FOR PROSTATE TREATMENT CONTAINING LYSYL-GLUTAMYL-ASPARTYL-PROLINE TETRAPEPTIDE | 2017 |
|
RU2640931C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING DISEASES OF LOWER PART OF GENITOURINARY SYSTEM | 2010 |
|
RU2428173C1 |
| AGENT FOR TREATMENT AND PROPHYLAXIS OF BENIGN PROSTATE HYPERPLASIA, PROSTATITIS, IMPOTENCE, INFERTILITY AND PROSTATE CANCER | 1998 |
|
RU2140265C1 |
| METHOD OF TREATING PROSTATE ADENOMA COMBINED WITH CHRONIC NONBACTERIAL PROSTATITIS | 2014 |
|
RU2568369C1 |
